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Value of MFC-MRD with Response Criteria in AML Risk Groups 18 
  19 
 1 
Abstract  2 
Purpose 3 
We investigated the effect on outcome of measurable/minimal residual disease (MRD) status after 4 
each induction course in order to evaluate the extent of its predictive value for acute myeloid 5 
leukemia (AML) risk groups including NPM1wild-type standard-risk when incorporated with other 6 
induction response criteria.   7 
 8 
Patients and Methods 9 
As part of the NCRI AML17 trial, 2450 younger adult patients with AML or high risk MDS had 10 
prospective flow cytometric MRD (MFC-MRD) assessment.  Post course-1 (C1) responses were 11 
categorised as resistant disease (RD), partial remission (PR) and CR/CRi by clinicians, with 12 
CR/CRi subdivided by MFC-MRD assay into MRD+ and MRD-.  Patients without high-risk factors, 13 
including Flt3ITDwild-type/-NPM1wild-type subgroup, received a second daunorubicin/ara-C 14 
induction; course-2 (C2) was intensified for high-risk.  15 
 16 
Results 17 
Survival outcomes from PR and MRD+ responses post-C1 were similar, particularly for 18 
good/standard-risk subgroups (5 year OS: 33%RD vs 49%PR vs 51%MRD+  vs 70%MRD-, 19 
p<.0001). Adjusted analyses confirmed significant OS differences between C1 RD vs PR/MRD+ 20 
but not PR vs MRD+.  CRi post-C1 reduced OS in MRD+ (19%CRi vs 45%CR, p=.001) patients 21 
with a smaller effect post-C2. 22 
The prognostic effect of C2 MFC-MRD status (relapse, HR 1.88(1.50- 2.36), p<0.001; survival, HR 23 
1.77(1.41-2.22) p<0.001) remained significant when adjusting for C1 response.  MRD-positivity 24 
appeared less discriminatory in poor-risk patients by stratified analyses.  For NPM1wild-type 25 
standard-risk subgroup, C2 MRD+ was significantly associated with poorer outcomes (OS, 32% vs 26 
64%MRD-, p=0.003; relapse incidence 89% when MRD+ ≥0.1%); transplant benefit was more 27 
apparent in MRD+(HR 0.72(0.31-1.69) than MRD-(HR 1.68(0.75-3.85); (p=0.16 for interaction). 28 
 29 
Conclusion MFC-MRD can improve outcome stratification by extending definition of partial 30 
response post first induction and may help predict NPM1wild-type standard-risk patients with poor 31 
outcome who benefit from transplant in CR1.  32 
 33 
 34 
Introduction 1 
In acute myeloid leukemia (AML) failure to achieve morphological complete remission (CR) after a 2 
first cycle of induction in previously untreated patients is an established independent prognostic 3 
factor from earlier studies1-3. Thus morphological response at this time-point is often incorporated 4 
with genetic and pre-treatment clinical parameters to guide further therapy4, including second 5 
induction courses, choice of consolidation and whether intensification from allogeneic stem cell 6 
transplantation (SCT) may be appropriate in otherwise intermediate risk patients. Despite 7 
morphological response criteria being standard, a different approach for measuring response has 8 
been proposed5,6 due to the independent prognostic value from measurable/minimal residual 9 
disease (MRD) assays when discrepant with morphology7-9 or in CR10-12 and the equivalent poor 10 
outcomes between MRD positivity and active disease pre-myeloablative SCT13,14  11 
Previous studies have shown the prognostic value of MRD monitoring by PCR for patients with 12 
validated molecular targets, usually after 2 courses of chemotherapy11,12,15.  Flow cytometric MRD 13 
(MFC-MRD) may identify as early as post course 1, patients with a poorer response despite 14 
achieving CR and is an assay that can be applied across AML genetic subgroups12,16-20.   There is 15 
however insufficient data to ascertain the relative prognostic impact of MFC-MRD positivity in CR 16 
post course 1 compared to morphological active disease; it is feasible that the outcomes of 17 
patients with detectable MRD resemble those of refractory patients who achieve the cytoreduction 18 
criteria for a morphological partial remission21,22.  Evaluating this will help refine which response 19 
categories are the most useful prognostic surrogate endpoints to assess effectiveness of the first 20 
induction course.   21 
It is also uncertain for patients who complete a second chemotherapy course whether the quality 22 
of response after course 1, with inclusion of MFC- MRD assessment, adds prognostic information 23 
to CR-MRD status post course 2. The value of MFC-MRD status to differentiate outcome at either 24 
time-point is likely to be heterogeneous between established risk subgroups due to disease, 25 
treatment and assay factors but the extent of this has not been established.   26 
Treatment decisions, including predicting the benefit of SCT, are particularly challenging for the 27 
standard-risk subgroup. MFC-MRD assays are most likely to influence therapeutic choices for 28 
NPM1-wild type standard-risk patients following recent data that post induction RT-qPCR 29 
quantitation of blood mutated transcripts reliably predicts outcome for NPM1-mutated patients23,24. 30 
There is thus a specific need to define the usefulness of MFC-MRD for risk stratification in this 31 
subgroup.   32 
In this study we aimed to determine the prognostic effect of MFC-MRD measurement incorporated 33 
into response assessment post induction courses for the different risk subgroups, including NPM1 34 
wild type standard-risk patients, in a large cohort of  younger AML patients who had undergone 35 
intensive treatment in the National Cancer Research Institute (NCRI) AML17 trial.  36 
Methods   1 
Patients 2 
Patients were enrolled in the NCRI AML17 trial (ISRCTN: 55675535) from April 6, 2009, to 3 
December 31, 2014. (A list of treatments is provided in Appendix, Fig. A1).  4 
The AML17 protocol was designed primarily for younger patients, generally age < 60 years. 5 
Patients with high risk myelodysplastic syndrome (MDS), which was defined as >10% marrow 6 
blasts at diagnosis, and secondary AML were eligible. Acute promyelocytic leukemia (APML) 7 
patients were not included in this MRD study. After first induction, patients were defined by risk of 8 
relapse, using a validated score comprising cytogenetics, WBC, age, secondary disease, 9 
morphological response to course-125,26 and FLT-3 ITD/ NPM1 mutation status.  10 
Morphological-based response criteria were 1) complete response (CR), < 5% blasts in a cellular 11 
bone marrow,  CRi when best response was with neutropenia <1000/μL or thrombocytopenia 12 
<100,000/μL; 2) partial remission (PR), decrease of pre-treatment bone marrow blast percentage 13 
by at least 50%  to 5 -15% in a cellular marrow (hematological recovery not required)1, 3) resistant 14 
disease (RD), >15% marrow blasts (patients surviving at least 7 days post completion of 15 
treatment).  Responses were classified by centers. 16 
Patients designated as favorable or standard-risk received the second daunorubicin/cytosine 17 
arabinoside course and were then randomized to receive either 1 or 2 courses of high-dose 18 
cytosine arabinoside. High-risk patients were offered a randomization between FLAG-Ida or 19 
daunorubicin/clofarabine with the intention of eventually proceeding to allogeneic stem cell 20 
transplantation (SCT).  FLT3-ITD mutant patients were directed to the Lestaurtinib randomisation 21 
until 2012. 22 
The trial was sponsored by Cardiff University, approved by Wales-REC3 and conducted in 23 
accordance with the Declaration of Helsinki. 24 
 25 
Multiparameter Flow Cytometry (MFC) detection of MRD 26 
Samples for MFC-MRD were requested at baseline (bone marrow and/or blood) and following 27 
each course (bone marrow). A summary of sample logistics and processing is provided in the 28 
Appendix. MFC-MRD analysis was performed centrally, using standardised gating strategy that 29 
screened for ‘different-from-normal’ LAIPs (Leukemia-Associated-Immunophenotypes) on blasts 30 
pre-treatment and tracked these (~0.02 -0.05% sensitivity thresholds)  but also applied the 31 
‘different-to-normal’ approach in follow-up (FU) samples to detect changes in blast LAIPs (~0.05 -32 
0.1% sensitivity threshold).  In this study only samples for which there were pre-treatment LAIPs to 33 
monitor could be reported as MFC-MRD-negative whilst samples with any level of MRD detected 34 
above a diagnostic-LAIP or different-from-normal FU-LAIP threshold were reported as MFC-MRD-35 
positive.  36 
Clinicians were not informed of MFC-MRD results.  37 
 1 
Statistical Analysis 2 
All end points were based on the revised criteria of the International Working Group for 3 
Diagnosis21.  Survival percentages were calculated using the Kaplan-Meier method with 4 
cumulative incidence of relapse calculated using competing risks methodology. Baseline 5 
characteristics were compared using chi-squared or Mantel-Haenszel tests, with continuous 6 
variables compared using the Wilcoxon rank sum test. Time-to-event outcomes were compared 7 
using logrank tests and Cox regression. Outcomes are reported as effect sizes with 95% 8 
confidence intervals; significance was set at p<.05. Stratified analyses use stratified logrank tests 9 
and are displayed as Forest plots with tests for interaction using standard methodology27. 10 
Comparison of transplantation versus not was analysed using the method of Mantel & Byar to 11 
mitigate immortal time bias. 12 
Median follow-up for survival was 39.0 months (range 1.0-80.5 months). 13 
 14 
 15 
 16 
 17 
  18 
Results 1 
Induction Response by Morphology and MFC-MRD: Patient Characteristics  2 
Between 2009 and 2014, 6539 samples (BM or PB at diagnosis, BM post treatment courses) from 3 
2450 non-APML patients recruited to AML17 were prospectively analysed for flow cytometric 4 
detection of MRD (MFC-MRD) (Appendix-Fig A2). Among patients in complete remission post 5 
course-1 (C1), the presence of MRD data was associated with secondary AML, and the absence 6 
of an NPM1 mutation (reflecting the prioritising of BM for RT-qPCR monitoring of NPM1 7 
mutations23 during the second phase of the trial); survival at 5 years was 52% (with MRD data) vs 8 
50% (without MRD data). In adjusted analyses, the presence of MRD data was not associated 9 
with survival (HR 0.99 (0.84-1.16) P =0.9). 10 
 Post-C1 1443 patients contributed data, 420 were refractory by morphology (197 resistant 11 
disease/ RD, 223 partial remission/ PR) and 1023 (70.9%) achieved morphological complete 12 
remission (CR/CRi) with MFC-MRD data (446 MFC-MRD negative [MRDneg], 577 MFC-MRD 13 
positive [MRDpos]).  After the second course of induction (C2), 806 patients were in CR/CRi with 14 
MFC-MRD data (503 MRDneg, 303 MRDpos).   15 
The clinical characteristics of patients according to response post-C1 and MRD status for patients 16 
in CR/CRi post-C1 or C2 are listed in Table 1.  There was a significant association between 17 
responses post course-1 or course-2 and cytogenetic group; however, count recovery post 18 
course-1 was not significantly associated with MRD post either course.  19 
 20 
Outcome Comparison for Morphologic Response and MFC-MRD Status after Course 1  21 
We evaluated overall survival (OS) by C1 response status.  Five year overall survival (OS) for all 22 
enrolled in AML17 excluding early deaths was 52% for those achieving CR/CRi vs 31% for 23 
refractory patients (P <.001).  MRD status in CR/CRi versus PR or RD further differentiated 5 year 24 
survival outcomes (Fig 1A).  A PR or MRDpos response gave intermediate survival at 5 years. 25 
Survival rates appeared equivalent between these two responses for the good / standard-risk 26 
patients; 5 year OS for MRDneg vs MRDpos vs PR vs RD were 63% vs 44% vs 35% vs 24% for 27 
all patients; 70% vs 51% vs 48% vs 27% when poor-risk patients excluded (Fig 1B); 66% vs 49% 28 
vs 46% vs 30% for standard-risk alone (Fig 1C) (P <.001 for all analyses). Similar results were 29 
observed for survival censored at SCT (Appendix-FigA3A, Fig 1D) and also for NPM1wild type 30 
(wt) standard-risk patients (Appendix-FigA3B-C).  31 
Adjusted analyses confirmed significant survival differences between RD and  PR / MRDpos but 32 
not between PR and MRDpos  for   good /standard-risk patients (RD vs PR /MRDpos, OS  HR 33 
2.28(1.38-3.75) P=.0009;  PR vs MRDpos, HR=1.32,P=0.4)  and for  NPM1wt standard-risk 34 
patients (RD vs PR /MRDpos , OS HR 2.13(1.21-3.75) P=.008;  PR vs MRDpos, HR=1.18,P=0.6) .  35 
Results were similar when censored at SCT (Table 2). 36 
Thus the prognostic effect from morphological response criteria post first induction is restricted to 1 
RD in in the good/ standard-risk subgroups when MFC-MRD status is incorporated into response 2 
assessment.   3 
Only 25 patients were refractory by morphology post-C1 but MRDneg (22 PR, 3 RD) with 61% 3-4 
year and 49% 5-year OS.  Seven of 577 MRDpos patients were in morphological CR but had ≥5% 5 
aberrant blasts by MFC (range 5.4-38%), Six died within 2 years, with one patient alive at 58.6 6 
months. 7 
 8 
Relative Prognostic Effect of MFC-MRD after Course 1 & Course 2 by Genetic / Risk Score 9 
Subgroup 10 
In AML17 patients received 2 courses of induction regardless of remission status after course 1 11 
but course 2 differed for patients designated as poor risk by trial risk score. Analyses of survival 12 
and relapse by MFC-MRD status of CR/CRi patients for C1  (n=1010) and C2 (n=803) were 13 
performed stratified by cytogenetic28 and trial risk subgroups (Fig 2, Appendix-FigA4) to 14 
investigate the relative prognostic impact from clearance of blasts below MFC-MRD detection 15 
threshold at either of these response assessment time–points. There was some evidence that the 16 
benefit from MFC-MRD negativity on OS was lower in poor-risk patients compared to other 17 
subgroups with the NCRI AML17 treatment schedule (test for trend; p=0.01 for C1, p=0.05 for C2). 18 
Overall MFC-MRD status appeared more prognostic for relapse and OS at C2 (relapse, OR 19 
1.88(1.50- 2.36), p<0.001; survival, HR 1.77(1.41-2.22) p<0.001) than C1 (relapse, HR 1.70(1.40- 20 
2.06), p<0.001; survival, HR 1.50(1.23-1.84) p<0.001) although this difference diminished when 21 
C1 analysis was restricted to patients who received course 2 and survived at least 30 days post-22 
C2 (relapse, HR 1.80(1.49-2.18) p<.0001; survival, HR 1.87 (1.52-2.29) p<.0001). 23 
Outcome from Combined Course 1 Response status and Course 2 MFC-MRD status 24 
In patients with response / MFC-MRD data for both C1 and C2 time points (n=693), C2 MFC-MRD 25 
positivity remained significant on OS and relapse when adjusting for C1 response (5 year survival, 26 
HR 1.79(1.38-2.32) P<.0001; relapse, HR 1.52(1.18-1.96) P=.001) (Fig 3). A small number of 27 
patients (n=24) patients converted from C1 MRDneg to C2 MRDpos, with a particularly poor 28 
prognosis (15 relapses, 13 deaths); one had adverse risk cytogenetics and 5 were Flt3ITD 29 
mutated (Appendix-Table A1). Patients who were MRDneg at both C1 and C2 had the best 30 
outcome (n=217, 67 relapses /57 deaths); of these 80.8% were good /standard-risk and 26.3% 31 
NPM1wt standard-risk (Appendix-Table A2). 32 
 33 
 34 
MRD status combined with peripheral count recovery 35 
We examined the additional prognostic effect from combining MRD status with response by 1 
peripheral count recovery post-C1 and C2 (Appendix-Table A3). The frequencies of CRi as best 2 
response in the total cohort were similar in MRDpos vs MRDneg patients post-C1 (9.3%vs 9.6%) 3 
and C2 (13.1%vs12.0%); CRi frequencies were not relatively increased in the NPM1wt standard-4 
risk subgroup.  C1 CRi was associated with significantly decreased 5 year OS for total (39% vs 5 
53%, p=.002) and in MRDpos (19% vs 45%, p=.001) but not for MRDneg patients.  MRDpos 6 
NPM1wt standard-risk-patients in CRi also had a lower OS at 5 years (25%vs 48%, p=0.4) 7 
although difference was not significant.  The effect of CRi vs CR was smaller post-C2 although 8 
outcomes were still worst in CRi/MRDpos patients. The reduced survival associated with CRi was 9 
not due to increased relapse. 10 
 11 
Outcome by MFC-MRD status for NPM1-wild type Standard-Risk Patients 12 
Since it is possible that the most appropriate MFC-MRD cut-off level for discriminating outcome  13 
may differ between AML genetic subgroups, we compared the 5 year cumulative incidence of 14 
relapse for C1 MRDneg vs MRDpos <0.1% vs MRDpos ≥0.1% by our assay in CBF-AML and   15 
NPM1-mutated as well as NPM1wt standard-risk patients.  For CBF-AML and NPM1-mutated post 16 
C1 MRDpos at any level (<0.1% or ≥0.1%) significantly increased relapse (Appendix-FigA5). 17 
However in the NPM1wt standard-risk subgroup, low level MRDpos (<0.1%) post-C1 did not alter 18 
relapse risk compared to MRDneg but was associated with a higher CIR when detected post-C2 19 
(Fig 4A).  MRDpos levels of ≥0.1% detected in 35% and 13% NPM1wt standard-risk patients post-20 
C1 and post-C2 respectively predicted a high probability of relapse (C1 3 year CIR 68%, C2 CIR 21 
89%). MRD status post second induction was also significantly prognostic for survival; 33% for any 22 
level of MRD positivity vs 63% for MRDneg at 5 years (3 years 47% vs 69%, P=.003) (Fig 4B).  23 
Of the 204 NPM1wt standard-risk patients with C2 MRD data, 83 had an allograft (44 in CR1: 29 24 
MRDneg, 15 MRDpos). When survival was censored at any SCT, rates of 5 year OS were 35% vs 25 
88% (3 years 47% vs 88%, P=.0005) (Appendix-FigA6). We next investigated the effect of SCT in 26 
CR1 according to C2 MRD status in Mantel-Byar analyses; although numbers were small, results 27 
suggested that transplant might be considered in MRDpos (HR 0.72(0.31-1.69) but not MRDneg 28 
patients (HR 1.68(0.75-3.85); p-value for interaction p=0.16) (Fig 4C). 29 
 30 
 31 
Discussion 32 
Response to induction therapy is a powerful prognostic indicator in AML. There are however 33 
differing practices for the implementation of technologies that measure residual leukemia to 34 
assess response. Flow cytometry is often used to support the definition of CR by morphology; 35 
those centres with access to experienced laboratories including some trial groups have extended 36 
its use to define CR without MRD5.  It has recently been reported that outcomes post 37 
myeloablative SCT for patients with pre-transplant flow cytometric MRD below 5% resemble those 1 
with at least 5% blasts by morphology13. This and the similar event-free survival observed in ~80 2 
pediatric patients with MRD positivity after first induction whether <5% or ≥ 5% blasts by 3 
morphology7  suggest that dichotomising patients by a 5% blast CR cut-off fails to capture some 4 
prognostic information.  Our results confirm this. By incorporating flow cytometric MRD with 5 
established response criteria of partial remission and resistant disease distinct prognostic groups 6 
emerge post first course of standard induction for 5 year survival. Importantly the response 7 
subgroup with intermediate outcome comprises patients on either side of the current CR blast 8 
threshold, those with MRD positivity in CR and those who are refractory but clinically classified as 9 
a PR; both responses are associated with very similar 5 year survival, particularly in patients 10 
otherwise allocated as good /standard-risk subgroups. This is also the case when PR is defined by 11 
ELN criteria5,21(Appendix-FigA7).  From this, 3 response categories post first induction could be 12 
proposed: resistant disease, partial responders (flow cytometric MRD-positive whether below or 13 
above 5% blast threshold) and CR/CRi without MRD.   CRi was an independent risk factor to MRD 14 
in a study that included relapsed/refractory AML and differing induction intensities29,30.  From our 15 
data, outcomes for newly diagnosed AML patients achieving negative MRD are equivalent 16 
between CRi and CR after a single standard induction.  However, the relatively few in our cohort 17 
(4.8%) with both CRi and MRD-positivity after first induction had as poor survival (OS 19% for all, 18 
25% NPM1wt standard-risk) as RD patients. 19 
 20 
For those completing a second induction with a CR/CRi, post course-2 MRD status increases 21 
prognostic discrimination. Although sample attrition bias may limit analyses comparing time-points, 22 
MRD negativity post course-2 improves outcome overall even when adjusting for slower blast 23 
clearance by course-1 response. This differs from our previous results in older adults17 and might 24 
reflect the better treatment tolerance and mutation profiles of younger adults. However following 25 
the second daunorubicin/cytosine arabinoside induction, ~33% of standard-risk /~34% of NPM1wt 26 
standard-risk patients in CR/CRi had persistent bone marrow MRD by our assay. Whether 27 
detectable MFC-MRD after completion of conventional induction is a sufficiently specific 28 
prognostic surrogate to guide therapy has been debated. The post-consolidation time-point was 29 
more informative in the GIMEMA study for a cohort that included ~70% with intermediate 30 
cytogenetics 31,32. This suggests that in a proportion of those with post-induction MRD positivity, 31 
consolidation may confer a favourable outcome by further MFC-MRD clearance (although it is of 32 
note that for some younger adults in the GIMEMA trials the induction/consolidation regime 33 
comprised 2 courses in total).  Genetic profile, treatment intensity and the later effects of any 34 
transplant may also modify interpretation and utility of MFC-MRD to inform post-remission therapy.  35 
Our data is consistent with this since the prognostic impact as well as best MFC-MRD cut-off level 36 
differed between AML risk groups; MRD status appeared less discriminatory in the poor-risk 37 
patients. Importantly however, in the NPM1wt standard-risk subgroup, detectable MFC-MRD at 1 
≥0.1% early in treatment is associated with significantly higher relapse rates (89% after second 2 
course). The ‘false negative’ 50% CIR observed for post induction MRD-negative NPM1wt 3 
standard-risk patients could reflect MFC-MRD sensitivity limitations although a  similar CIR was 4 
observed for DNTM3A-mutated /NPM1-mutated patients who were MRD-negative by NPM1-5 
mutated transcript RT-qPCR23.  Exploratory analyses could not identify any significant clinical 6 
parameters that predicted MRD-negative relapses.  Longitudinal broad molecular studies may 7 
disclose whether increased pre-leukemic instability re-initiating AML33,34 or persistence of pre-8 
treatment minor or major leukemic clones35,36 contributes to these ‘false-negative’ relapse risks.  9 
Notwithstanding, NPM1wt standard-risk patients achieving MRD negativity post second induction 10 
had a significantly better survival. As their survival increased to 88% when censored for transplant, 11 
this raises the possibility that transplant in first remission could be avoided in this subset. The 12 
Mantel-Byar analysis support this with some evidence of interaction, although this should be 13 
interpreted cautiously as small numbers and the interaction was not significant. 14 
Transplant decisions have mainly been arbitrary in this subgroup with no accepted approach to 15 
distinguish those patients likely to be cured with chemotherapy alone (or those likely to be 16 
successfully salvaged if they do relapse) from those who benefit from transplantation in first 17 
remission or potentially experimental therapy. Our results suggest that allogeneic transplant in first 18 
remission could be directed to those who are MRD-positive rather than MRD-negative. This is the 19 
first indication that MRD status might have utility directing therapy for NPM1wt standard-risk 20 
patients despite their molecular heterogeneity. Large patient data sets likely requiring collaborative 21 
efforts will determine whether integrating MFC-MRD status with genomic profiles37,38 further 22 
informs outcome prediction. 23 
 24 
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 2 
Figure Legends  3 
 4 
Figure 1. Overall Survival according to post course 1 response status.   5 
(A) all patients (B) good and standard risk patients (known poor risk excluded) C) standard-risk 6 
patients  D) OS for standard-risk patients  censored at allogeneic stem cell transplantation 7 
 8 
RD, refractory disease; PR, partial remission; CR, complete remission; MRD, measurable residual 9 
disease; MRD-, MRD negative; MRD+, MRD positive; ASCT, allogeneic stem cell transplantation 10 
 11 
Figure 2. Forest Plots for Overall Survival by MFC - MRD status for patients in CR  (A) post 12 
course 1, (B) post course 2  stratified by cytogenetic risk group and NCRI AML17 risk score group  13 
CR, complete remission; MRD, measurable residual disease; MRD -, MRD negative; MRD+, MRD 14 
positive 15 
Figure 3. Forest Plots for (A) Overall Survival and (B) Relapse by combined post course 1 and 2 16 
response data. 17 
 Effect of MFC-MRD status in CR post course 2 stratified by post course 1 response status 18 
CR, complete remission; RD, refractory disease; PR, partial remission; MRD, measurable residual 19 
disease; MRD-, MRD negative; MRD+, MRD positive 20 
Figure 4.  Standard-risk NPM1-wild type:   (A) Cumulative Incidence of Relapse (CIR) by MRD 21 
level  22 
(MRD– vs MRD+ <0.1% vs MRD+ ≥ 0.1%) post course 1 and post course 2,  23 
(B) Overall Survival according to post course 2 MRD status, MRD- vs MRD+.  24 
(Not shown: MRD+ ≥ 0.1%, overall survival of 24%; MRD+ <0.1%, overall survival of 39%)  25 
(C) Mantel Byar for survival according to CR1 SCT by MRD status post course 2 26 
MRD, measurable residual disease; MRD-, MRD negative; MRD+, MRD positive 27 
 28 
SCT, allogenic stem cell transplant; CR1, first CR; MRD-, MRD negative; MRD+, MRD positive 29 
In Appendix   30 
Appendix Figure A1.  Flow chart for treatments given to patients in NCRI AML17  31 
 32 
Appendix Figure A2.  CONSORT: Outline of patient sample flow for MRD study  33 
 34 
Appendix Figure A3. OS according to post course 1 response status.  (A) All patients, OS 35 
censored at allogeneic stem cell transplantation, (B) NPM1 wild type standard risk patients, (C) 36 
NPM1 wild type standard risk patients, censored at allogeneic stem cell transplantation 37 
OS, overall survival; RD, resistant disease; PR, partial remission; CR, complete remission; MRD, 1 
measurable residual disease; MRD-, MRD negative; MRD+, MRD positive;  SCT, allogeneic stem 2 
cell transplantation 3 
Appendix Figure A4.  Forest Plots for Relapse by FCM - MRD status for patients in CR (A) post 4 
course 1, (B) post course 2 stratified by cytogenetic risk group and NCRI AML 17 risk score group  5 
CR, complete remission; MRD, measurable residual disease; MRD-, MRD negative; MRD+, MRD 6 
positive 7 
Appendix Figure A5.  Cumulative Incidence of Relapse (CIR) by MFC-MRD level  8 
(MRD- vs MRD+ <0.1% vs MRD+ ≥ 0.1%) post course 1  9 
(A) CBF AML (B) Standard Risk NPM1 Mutant 10 
MRD, measurable residual disease; MRD-, MRD negative; MRD <0.1%, MRD positive <0.1%;  11 
MRD 0.1%+, MRD positive ≥ 0.1% 12 
 13 
 14 
Appendix Figure A6. Standard Risk NPM1wild type: Overall Survival according to post course 2 15 
FCM-MRD status, censored at any allogeneic stem cell transplantation 16 
CR, complete remission; MRD, measurable residual disease; MRD-, MRD negative; MRD+, MRD 17 
positive 18 
 19 
Appendix Figure A7. OS according to post course 1 response status applying ELN /Cheson 20 
criteria for PR and RD instead of MRC criteria.  (A) All patients. (B) good and standard risk 21 
patients (known poor risk excluded)  (C) standard risk patients, (D) standard risk patients, OS 22 
censored at allogeneic stem cell transplantation. 23 
OS, overall survival; RD, resistant disease by ELN defintion; PR, partial remission by ELN 24 
definition; CR, complete remission; MRD, measurable residual disease; MRD-, MRD negative; 25 
MRD+, MRD positive;  SCT, allogeneic stem cell transplantation 26 
ELN criteria for PR: all hematologic criteria of CR; decrease of bone marrow blast percentage to 27 
5% to 25% with decrease of pretreatment bone marrow blast percentage by at least 50% 28 
 29 
 30 
 31 
 32 
 33 
 34 
A       Overall Survival All patients B Overall Survival Excluding Poor Risk
FIGURE 1A - D
C Overall Survival Standard Risk D Overall Survival Standard Risk censored at SCT
Figure 2A:  Effect of FCM-MRD status post course 1 stratified by cytogenetic and risk score group
Overall Survival
MRD status post C1 
Figure 2B:  Effect of FCM-MRD status post course 2 stratified by cytogenetic and risk score group
Overall Survival
MRD status post C2 
MRD status in CR post C2 
Figure 3A: Combined  post course 1 and 2 response status 
Overall Survival
Figure 3B: Combined  post course 1 and 2 response status 
Relapse
MRD status  in CR post C2 
A CIR by post course 1  FCM-MRD level CIR by post course 2  FCM-MRD level
Standard Risk NPM1wt 
Figure 4
B Overall Survival by post course 2 FCM-MRD
C Mantel-Byar analysis of CR1 allograft in Standard Risk NPM1wt by post course 2 MRD 
Table 1: Characteristics of Study Population by Response 
  
Post Course 1  Response  
(n= 1443) 
 
Post Course 2  MRD status in CR 
(n= 806) 
  
MRD- 
No. (%) 
 
MRD+ 
No. (%) 
 
PR 
No. (%) 
   
RD 
No. (%) 
P-value 
MRD-  
vs MRD+ 
P-value  
(4 
categories) 
P-value 
MRD+  
vs  PR 
 
MRD- 
No. (%) 
 
MRD+ 
No. (%) 
 
P-value 
All patients 446 
(30.9%) 
577 
(40.0%) 
197 
(13.7%) 
223 
(15.5%)    
503 
(62.4%) 
303 
(37.6%) 
 
Age, years 
16-29 
30-39 
40-49 
50-59 
60+ 
 
48  (10.8) 
59   (13.2) 
104 (23.3) 
145 (32.5) 
90  (20.2) 
 
67 (11.6) 
55 (9.5) 
135 (23.4) 
187 (32.4) 
133 (23.1) 
 
22 (11.2) 
15 (7.6) 
36 (18.3) 
75 (38.1) 
49 (24.9) 
 
26 (11.7) 
24 (10.8) 
39 (17.5) 
68 (30.5) 
66 (29.6) 
    
 67 (13.3) 
 64 (12.7) 
122 (24.3) 
168 (33.4) 
  82 (16.3) 
 
29 (9.6) 
33 (10.9.) 
62 (20.5) 
99 (32.7) 
80 (26.4.) 
 
Median Age, years (range) 50  
(16-71) 
51  
(16-72) 
53 
 (16-72) 
53  
(17-73) 
0.3** 0.02** 0.3** 49  
(16-72) 
53  
(16-72) 
0.002** 
Sex 
Female 
Male 
 
220 (49.3) 
226 (50.7) 
 
250 
(43.3.) 
327 (56.7) 
 
 
 85 (43.1.) 
112 (56.9) 
 
 91 (40.8.) 
132 
(59.2.) 
0.06 0.03* 1.0  
248 (49.3.) 
255 (50.7.) 
 
119 (39.3.) 
184 (60.7.) 
.006 
Diagnosis 
De Novo 
Secondary 
High risk MDS 
 
410 (91.9.) 
18  (4.0.) 
18  (4.0) 
 
492 (85.3) 
52   (9.0.) 
33   (5.7) 
 
162 
(82.2.) 
 23 (11.7) 
12  (6.1) 
 
193 
(86.5.) 
 25 (11.2) 
  0  (0)  
0.007 0.0009 0.5  
459 (91.3.) 
 25 (5.0) 
 19 (3.7) 
 
265 (87.5.) 
 26  (8.6.) 
 12  (4.0) 
0.12 
WHO Performance Status 
0 
1 
2 
3 
4 
 
 
314 (70.4) 
115 (25.8) 
11 (2.5) 
5 (1.1) 
1 (0.2) 
 
 
413 (71.6) 
138 (23.9) 
14 (2.4) 
12 (2.1) 
0 (0) 
 
 
138 (70.1) 
53 (26.9) 
4 (2.0) 
2 (1.0) 
0 (0) 
 
 
148 (66.4) 
65 (29.1) 
6 (2.7) 
4 (1.8) 
0 (0)71.4 
1.0* 0.4* 0.8*  
 
359 (71.4) 
124 (24.7) 
13 (25.8) 
6 (1.2) 
1 (0.1) 
 
 
219 (72.3) 
72 (23.8) 
9 (3.0) 
3 (1.0) 
0 (0) 
0.7* 
WBC (x109/L) 
0-9.9 
10-49.9 
50-99.9 
 
219 (49.1) 
156 (35.0) 
42 (9.4) 
 
301 (52.2) 
186 (32.2) 
45 (7.8) 
 
114 (57.9) 
47 (23.9) 
21 (10.7) 
 
112 (50.2) 
55 (24.7) 
26 (11.7) 
    
260 (51.7) 
166 (33.0) 
46 (9.1) 
 
155 (51.2) 
88 (29.0) 
29 (9.6) 
 
100+ 29 (6.5) 45 (7.8) 15 (7.6) 30 (13.5) 31 (61.6) 31 (10.2) 
Median WBC (x109/L) 
 (range) 
 
 
10.6 (0.3-
319.6) 
8.9  
(0.4-
456.0) 
6.0  
(0.4-
430.0) 
9.9  
(0.6-
430.0) 
0.3** 0.3** 0.13** 9.3  
(0.7-275.2) 
9.5  
(0.4-430.0) 
0.5** 
Cytogenetics 
Favorable 
Intermediate 
Adverse 
Unknown 
 
82 (18.4) 
322 (72.2) 
27 (6.1) 
15 (3.3) 
 
75 (13.0) 
386 (66.9) 
87 (15.1) 
28 (4.9) 
 
8 (4.1) 
126 (64.0) 
53 (26.9) 
10 (5.1) 
 
3 (1.3) 
130 (58.3) 
79 (35.4) 
11 (4.9) 
<.0001* <.0001* <.0001*  
94 (18.7) 
349 (69.4) 
36 (7.2) 
24 (4.8) 
 
18 (5.9)  
208 (41.4) 
59 (11.7) 
17 (3.4) 
<.0001 
FLT3-ITD / NPM1c Status 
ITD WT, NPM1c WT 
ITD WT, NPM1c mutant 
ITD mutant, NPM1c WT 
ITD mutant, NPM1c mutant 
Unknown 
 
229 (51.3) 
99 (22.2) 
22 (5.0) 
63 (14.1) 
33 (7.4) 
 
356 (61.7) 
88 (15.3) 
42 (7.3) 
63 (10.9) 
28 (4.9) 
 
129 (65.5) 
18 (9.1) 
17 (8.6) 
12 (6.1) 
21 (10.7) 
 
174 (78.0) 
8 (3.6) 
29 (13.0) 
5 (2.2) 
7 (3.1) 
.001 <.0001 0.05  
274 (54.5 ) 
102 (20.3 ) 
27 (5.4) 
66 (13.1 ) 
34 (6.8) 
 
192 (63.4) 
39 (12.9 ) 
24 (7.9 ) 
28 (9.2 ) 
20 ( 6.6) 
0.005 
Post-course 1  Response 
CR  
CRi  
PR 
RD 
 
407 (91.3) 
39 (8.7) 
 
528 (91.5) 
49  (8.5) 
  0.9    
412 (81.9 ) 
37 (7.4) 
26 (5.2 ) 
22 (4.4 ) 
6 (1.2 ) 
 
219 (72.3) 
18 (5.9) 
33 (10.9) 
28 (9.2) 
5 (1.7) 
<.0001*; 
CR vs 
CRi 
(p=0.8) 
   
Post-course 1 Risk Score 
Good 
Standard 
Poor Risk 
Not Assessable 
 
86 (19.3) 
253 (56.7) 
102 (22.9) 
6 (1.3) 
 
85  (14.7) 
267 (46.3) 
218 (37.8) 
6  (1.0) 
 
11 (5.6) 
42 (21.3) 
138 (70.1) 
6 (3.0) 
 
3 (1.3) 
37 ( 16.6) 
167 (74.9)  
16 (7.2) 
<.0001* <.0001* <.0001*  
102 (20.3) 
267 (53.1) 
132 (26.2) 
2 (0.4) 
 
30 (9.9 ) 
131 (43.2) 
141 (46.5) 
1 (0.3) 
<.0001* 
Number of Chemotherapy 
Cycles (poor risk excluded) 
3 
4 
Not Randomised  
 
 
95 (21.3) 
117 (26.2) 
139 (31.2) 
 
 
128  
(22.2) 
116  
(20.1) 
130  
(22.5) 
 
 
12 (6.1) 
10 (5.1) 
37 (18.8) 
 
 
0 (0 ) 
1 ( 0.4) 
56 (25.1 ) 
n/a n/a n/a  
 
113 (22.5) 
139 (27.6 
128 (25.4) 
 
 
64 (21.1) 
49 (16.2 ) 
56 (18.5 ) 
n/a 
Allogeneic SCT 
Any 
CR1 
 
142 (31.8) 
82 (18.4) 
 
215 (37.3) 
128 (22.2 
 
102 (51.8) 
75 (38.1 
 
89 (39.9 ) 
71 (31.8 ) 
0.07  0.0008* 0.01  
193 (38.4 ) 
114 (22.7 ) 
 
139 (45.9) 
91 (30.0) 
0.04 
CR2 38 (8.5) 68 (11.8) 4 (2.0) 2 (0.9 ) 54 ( 10.7) 32 (10.6 ) 
 
 
Chi-square test unless specified otherwise. *: Mantel-Haenszel test for trend;**: Wilcoxon rank sum test/Spearman correlation; n/a not assessed as 3 v 4 
courses randomised.  
 
MRD, measurable residual disease by flow cytometry; MRD+, MRD positive; MRD- , MRD negative; CR, Complete Remission; CRi, complete remission with 
absolute neutrophil count <1,000/µl or thrombocytopenia <100,000/μ; RD, Resistant Disease (less than a 50% reduction in blast numbers with >15% residual 
blasts) PR, Partial Response  (at least a 50% reduction in blast numbers with 5% -15% residual blasts 
 
  
Table 2:  Outcomes by post course 1 response status  
  
 
  
           PR   MRD+  in CR 
Unadjusted 
HR/OR,  
95% CI; p-value 
adjusted HR/OR, 
 95% CI; p-value 
RD 
PR or  
MRD+  in CR 
Unadjusted 
HR/OR,  
95% CI; p-value 
adjusted HR/OR,  
95% CI; p-value 
 
All patients 
 
N= 197 
 
N= 577 
   
N= 223 
 
N= 774 
  
5yr  (3yr) OS 35% (41%) 44% (51%) 1.50 (1.18-1.91) 
P=.001 
1.32 (1.05-1.66) 
p=0.02 
24% (30%) 41% (48%) 2.43 (1.93-3.06) 
p<.0001 
1.61 (1.31-1.97) 
p<.0001 
5yr (3yr) OS censored 
at SCT 
41% (48%) 49% (54%) 1.81 (1.25-2.61) 
P=.002 
1.62 (1.16-2.25) 
p=0.004 
11% (11%) 48% (53%) 8.17 (5.76-11.6) 
p<.0001 
2.64 (2.02-3.45) 
p<.0001 
 
Good / Standard Risk 
patients 
 
N= 53 
 
N= 352 
   
N= 40 
 
N= 405 
  
5yr  (3yr) OS 49% (58%) 51% (59%) 1.11 (0.69-1.76) 
P=0.7 
1.320 (0.65-2.68) 
P=0.4 
33% (33%) 51% (59%) 16.6 (9.24-30.0) 
P<.0001 
2.28 (1.38-3.75) 
p=.0009 
5yr (3yr) OS censored 
at SCT 
67% (73%) 60% (66%) 1.05 (0.54-2.06) 
P=0.9 
1.38 (0.68-2.80) 
P=0.4 
37% (at 3, 4 yrs) 61% (67%) 22.4 (8.23-60.8) 
P<.0001 
3.56 (1.78-7.12) 
p=.0002 
 
 Standard Risk NPM1 
WT patients 
 
N= 27 
 
N= 149 
   
N= 34 
 
N= 176 
  
5yr (3yr) OS 38% (55%) 47% (55%) 1.10 (0.60-2.04) 
P=0.8 
1.18 (0.61-2.28) 
P=0.6 
28% (28%) 45% (55%) 3.09 (1.65-5.80) 
p=0.0004 
2.13 (1.21-3.75) 
p=.008 
5yr  (3yr) OS censored 
at SCT 
53% (71%) 52% (59%) 1.38 (0.52-3.63) 
P=0.5 
1.51 (0.58-3.93) 
P=0.4 
28% (at 3 yrs) 53% (60%) 18.2 (6.38-52.1) 
p<.0001 
3.88 (1.68-8.94) 
p=0.001 
 
PR , morphological partial response; CR, morphological complete remission; MRD+, MRD positive; CRi, complete remission with absolute neutrophil count 
<1,000/µl or thrombocytopenia <100,000/μl; OS – overall survival; SCT – allogeneic stem cell transplant; RFS– relapse free survival ; CIDCR – cumulative 
incidence of death in remission. 
Adjusted analyses included age, wbc, sex, performance status, disease type (secondary or de novo) and cytogenetic group. 
 
 
  
Appendix Table A1 
karyotype Cytogenetic 
risk group  NPM1 mutation  Flt3 ITD 
46,XY,t(8;21)(q22;q22)[7]/47,idem,+8[3] good negative negative 
46,XY[20] intermediate NA NA 
46,XY[20] intermediate + + 
46,XY[20] intermediate + + 
46,XX[16] intermediate + + 
46,XX[20] intermediate negative + 
46,XY[20] intermediate negative + 
46,XX[20] intermediate + negative 
46,XY[20] intermediate negative negative 
46,XX[20] intermediate negative negative 
46,XX[20] intermediate negative negative 
46,XX[20] intermediate negative negative 
46,XX,t(11;19)(q23;p13.1)[10] intermediate negative negative 
46,XY,del(9)(q?2q?3)[9]/46,XY[2] intermediate negative negative 
46,XX,t(2;9)(p22;p21)[12]/46,XX[1] intermediate negative negative 
46,XY,t(6;9)(p23;q24)[9]/46,XY[1] intermediate negative negative 
46,XY[20] intermediate negative negative 
45,XX,dic(17;18)(p11.2;p11.2)[9]/46,XX[
1] intermediate negative negative 
46,XX[20] intermediate negative negative 
46,XY[20] intermediate negative negative 
47,XY,+8[6]/ 46,XY[4] intermediate negative negative 
50,XY,+X,+4,t(10;11)(p12;q14),+15,+19
[9]/ 46,XY[1] adverse negative negative 
Failed NA negative negative 
Failed NA negative negative 
Table A2: Correlation of Risk group and Clinical Response by combined C1 and C2 response status  
 
C1, course 1 induction; C2, course 2 induction; MRD, measurable residual disease by flow cytometry; MRD+, MRD positive; MRD- , MRD negative; 
CR, Complete Remission; CRi, complete remission with absolute neutrophil count <1,000/µl or thrombocytopenia <100,000/μl; RD, Resistant Disease 
(less than a 50% reduction in blast numbers with >15% residual blasts; PR, Partial Response  (at least a 50% reduction in blast numbers with 5% -15% 
residual blasts 
 
 
  
  
All 
 
 
No. (%) 
C1 MRD-   
C2 MRD-   
 
No. (%) 
C1 MRD-     
C2 MRD+ 
 
No. (%) 
 
C1 MRD+   
C2 MRD- 
 
No. (%) 
 
C1 MRD+   
C2 MRD+ 
 
No. (%) 
 
C1 PR   
C2 MRD-   
 
No. (%) 
 
C1 PR   
C2 MRD+ 
 
No. (%) 
 
C1 RD   
C2 MRD-   
 
No. (%) 
 
C1 RD   
C2 MRD+ 
 
No. (%) 
 
 
All  
(patients with  
both C1 and C2 data) 
 
 
693 
 
224 (32.3) 
 
24 (3.5) 
 
166 (24.0) 
 
170 (24.5) 
 
26 (3.8) 
 
33 (4.8) 
 
22 (3.2) 
 
28 (4.0) 
Post-course 1 Risk Score 
Good 
Standard 
Poor Risk 
Not Assessable 
 
110 (15.9) 
347 (50.1) 
234 (33.4) 
2     (0.3) 
 
48   (21.4) 
133 (59.4) 
41   (18.3) 
2      (0.9) 
 
2 (8.3) 
15 (62.5%) 
7 (29.2) 
0 
 
34 (20.5) 
87 (52.4) 
45 (27.1) 
0 
 
19 (11.2) 
87 (51.2) 
64 (37.6) 
0 
 
2 (7.7) 
12 (46.2) 
12 (46.2) 
0 
 
3 (9.1) 
4 (12.1) 
26 (78.8) 
0 
 
1 (4.5) 
6 (27.3) 
15 (68.2) 
0 
 
1 (3.6) 
3 (10.7) 
24 (85.7) 
0 
 
NPM1wt standard risk 
 
 
180 (26) 
 
59    (26.3) 
 
10 (41.2) 
 
50 (30.1) 
 
43 (25.3) 
 
8 (30.8) 
 
4 (12.1) 
 
6 (27.3) 
 
3 (10.7) 
Post-course 1  Response 
CR (excluding CRi/CRp) 
CRi / CRp 
 
 
538 (77.6) 
46 (6.6) 
 
202 (90.2) 
22  (9.8) 
 
23 (95.8) 
1 (4.2) 
 
157 (94.6) 
9 (5.4) 
 
156 (91.8) 
14 (14.4) 
    
Appendix Table A3 Outcomes for patients by peripheral count recovery response combined with MRD status 
 
  No.  (%CRi) 5 year  (3 year) OS p- value 5 year (3 year) CIR p- value 
All Patients 
 
 
Post Course 1 
CR vs CRi  
MRD- CR vs MRD- CRi  
MRD+ CR vs MRD+ CRi  
 
 
933 / 88   (9.4%) 
407 / 39   (9.6%) 
526 /49    (9.3%) 
 
 
53% vs 39% (60% vs 46%) 
63% vs 63% (70% vs 63%) 
45% vs 19% (52% vs 33%)  
 
 
0.002 
0.2 
0.001 
 
 
50% vs 43% (46% vs 40%) 
40% vs 33% (35% vs 33%) 
58% vs 53% (54% vs 47%) 
 
 
0.6 
0.7 
0.6 
Post Course 2 
CR vs CRi  
MRD- CR vs MRD- CRi  
MRD+ CR vs MRD+ CRi  
 
716 / 89   (12.4%) 
449 / 54   (12.0%) 
267 /35   (13.1%) 
 
54% vs 38% (59% vs 46%) 
63% vs 52% (68% vs 52%) 
37% vs 20% (46% vs 40%) 
 
0.02 
0.05 
0.3 
 
51% vs 47% (48% vs 44%) 
61% vs 57% (59% vs 57%) 
45% vs 40% (41% vs 36%) 
 
 
0.9 
0.9 
0.9 
Standard Risk 
NPM1 wt 
 
 
Post Course 1 
CR vs CRi  
MRD- CR vs MRD- CRi  
MRD+ CR vs MRD+ CRi 
 
241 / 19   (7.9%) 
100 / 11  (11.0%) 
141 /8     (5.7%) 
 
52% vs 42% (64% vs 56%) 
60% vs 64% (77% vs 64%) 
48% vs 25% (55% vs 50%) 
 
0.16 
0.2 
0.4 
 
58% vs 66% (53% vs 66%) 
49% vs 66% (41% vs 66%) 
65% vs 69% (61% vs 69%) 
 
0.2 
0.07 
0.8 
 Post Course 2 
CR vs CRi  
MRD- CR vs MRD- CRi  
MRD+ CR vs MRD+ CRi 
 
180 / 24 (13.3%) 
118/ 16  (13.6%) 
62 /8    (12.9%) 
 
54% vs 47% (63% vs 47%) 
63% vs 61% (70% vs 61%) 
35% vs 23% (50% vs 23%) 
 
0.3 
0.6 
0.10 
 
58% vs 43% (55% vs 43%) 
52% vs 34% (48% vs 34%) 
70% vs 67% (70% vs 67%) 
 
0.6 
0.5 
0.7 
 
MRD, measurable residual disease by flow cytometry; MRD+, MRD positive; MRD- , MRD negative; CR, Complete Remission; CRi, complete 
remission with absolute neutrophil count <1,000/µl or thrombocytopenia <100,000/μl; 
 
